Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Feb
08
Today In Oncology
A Paradigm Shift In Treating Adult AML?
Lymph Node Examination Should be Expanded to Accurately Assess Metastasis in NSCLC, Research Says
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
Agent Orange Exposure Linked With Risk for Acral Melanoma in Veterans
FDA Provides Safety Labeling Update for Capecitabine and Fluorouracil on Risks Associated With DPD Deficiency
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo